Kahn Harriette J, Presta Anthony, Yang Lu-Ying, Blondal John, Trudeau Maureen, Lickley Lavina, Holloway Claire, McCready David R, Maclean Daniel, Marks Alexander
Department of Pathology, Sunnybrook and Women's College Health Sciences Centre (SWCHSC), Toronto, Ontario, Canada.
Breast Cancer Res Treat. 2004 Aug;86(3):237-47. doi: 10.1023/B:BREA.0000036897.92513.72.
The biological and clinical significance of circulating tumor cells (CTC) in the peripheral blood of breast cancer patients is not known. To study this question, we used a direct visualization assay to correlate the number of CTC with disease stage and progression. The CTC were enriched from the nucleated cell fraction by filtration and enumerated visually following immunostaining with anti-cytokeratin 8 (CK8) antibody CAM 5.2. In mixing experiments, we achieved a limit of detection of 5 MCF7 cells per 5 ml of blood or 5 x 10(7) peripheral blood leukocytes (PBL). We did not detect CTC in any control subjects (0/20). In 131 breast cancer patients, we found a higher incidence of CTC in patients with distant metastatic 36/51 (71%) than those with node-positive 17/36 (47%) (p = 0.026), or node-negative 17/44 (39%) (p = 0.001) disease. The distribution of the highest numbers of CTC observed in individual patients by repeated sampling over time ranged from 1 to 700 per 5 ml of blood with a trend toward higher numbers in those with distant metastases. In comparison with previous studies of equal specificity, based on a similar absence of CTC in controls, we report a higher incidence of CTC in node-negative and node-positive patients, suggesting a more frequent detection of CTC by our approach. This higher incidence was achieved, in part, by repeated sampling of our study population over time. Our results support the concept that CTC can be detected and enumerated in peripheral blood and that this minimally invasive assay merits further evaluation as a potential prognostic indicator and marker of disease progression.
乳腺癌患者外周血中循环肿瘤细胞(CTC)的生物学及临床意义尚不清楚。为研究这一问题,我们采用直接可视化检测法,将CTC数量与疾病分期及进展相关联。通过过滤从有核细胞组分中富集CTC,并在用抗细胞角蛋白8(CK8)抗体CAM 5.2进行免疫染色后进行可视化计数。在混合实验中,我们实现了每5毫升血液或5×10⁷外周血白细胞(PBL)中检测到5个MCF7细胞的检测限。我们在任何对照受试者中均未检测到CTC(0/20)。在131例乳腺癌患者中,我们发现远处转移患者36/51(71%)的CTC发生率高于淋巴结阳性患者17/36(47%)(p = 0.026),或淋巴结阴性患者17/44(39%)(p = 0.001)。通过对个体患者随时间进行重复采样,观察到的每5毫升血液中最高CTC数量分布范围为1至700,远处转移患者的数量有更高的趋势。与基于对照中类似的CTC缺失情况的同等特异性的先前研究相比,我们报告淋巴结阴性和淋巴结阳性患者中CTC的发生率更高,表明我们的方法能更频繁地检测到CTC。这种更高的发生率部分是通过对我们的研究人群随时间进行重复采样实现的。我们的结果支持这样的概念,即外周血中可以检测和计数CTC,并且这种微创检测作为一种潜在的预后指标和疾病进展标志物值得进一步评估。